{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:48:23Z","timestamp":1790074103421,"version":"4.0.1"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/cji.0b013e31815b69c8","type":"journal-article","created":{"date-parts":[[2008,2,5]],"date-time":"2008-02-05T08:00:58Z","timestamp":1202198458000},"page":"132-147","source":"Crossref","is-referenced-by-count":51,"title":["Chemotherapeutic Drugs may be Used to Enhance the Killing Efficacy of Human Tumor Antigen Peptide-specific CTLs"],"prefix":"10.1097","volume":"31","author":[{"given":"Pierpaolo","family":"Correale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"La Placa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppa","family":"Di Genova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni Gori","family":"Savellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Terrosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210227","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.4049\/jimmunol.178.4.1975","article-title":"Unique human tumor antigens: immunobiology and use in clinical trials","volume":"178","author":"Parmiani","year":"2007","journal-title":"J Immunol"},{"key":"R2-3-20210227","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/08830180600992472","article-title":"Overview of tumor cell-based vaccines","volume":"25","author":"Copier","year":"2006","journal-title":"Int Rev Immunol"},{"key":"R3-3-20210227","first-page":"687","article-title":"Immune based therapies in cancer","volume":"22","author":"Kruger","year":"2007","journal-title":"Histol Histopathol"},{"key":"R4-3-20210227","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14712598.7.4.543","article-title":"PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma","volume":"7","author":"Madan","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"R5-3-20210227","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/MOU.0b013e3280eb10eb","article-title":"Prostate cancer immunotherapy","volume":"17","author":"McNeel","year":"2007","journal-title":"Curr Opin Urol"},{"key":"R6-3-20210227","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1084\/jem.173.1.273","article-title":"Human T lymphocytes recognize a peptide of single point-mutated oncogenic ras proteins","volume":"173","author":"Jung","year":"1991","journal-title":"J Exp Med"},{"key":"R7-3-20210227","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/eji.1830230905","article-title":"In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53","volume":"23","author":"Houbiers","year":"1993","journal-title":"Eur J Immunol"},{"key":"R8-3-20210227","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/87.13.982","article-title":"Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine","volume":"87","author":"Tsang","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"R9-3-20210227","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/89.4.293","article-title":"In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen","volume":"89","author":"Correale","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"R10-3-20210227","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.161.6.3186","article-title":"Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide","volume":"161","author":"Correale","year":"1998","journal-title":"J Immunol"},{"issue":"12","key":"R11-3-20210227","first-page":"2439","article-title":"Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen","volume":"3","author":"Tsang","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R12-3-20210227","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0952-7915(96)80078-1","article-title":"Human tumor antigens recognized by T cells","volume":"8","author":"Robbins","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"R13-3-20210227","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-065X.1999.tb01331.x","article-title":"Human tumor antigens for cancer vaccine development","volume":"170","author":"Wang","year":"1999","journal-title":"Immonol Rev"},{"key":"R14-3-20210227","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.4049\/jimmunol.169.9.4840","article-title":"High affinity HLA-A(*)02.01 peptides from parathyroid-hormone related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects","volume":"169","author":"Francini","year":"2002","journal-title":"J Immunol"},{"key":"R15-3-20210227","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/jnci\/dji188","article-title":"In vitro and in vivo generation of a multi-epitope CTL response with anti-tumor activity by using a poly-epitope peptide containing multiples HLA-A(*)02.01 binding motifs of thymidylate synthase, a molecular structure which is the critical target for tumor cell proliferation and response to 5-fluorouracil","volume":"97","author":"Correale","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R16-3-20210227","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ijc.10969","article-title":"5-Fluorouracil (5-FU) enhances the susceptibility of colon and breast carcinoma cells to human carcino embryonic (CEA) peptide-specific cytotoxic T cells in vitro","volume":"104","author":"Correale","year":"2003","journal-title":"Int J Cancer"},{"key":"R17-3-20210227","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immuno-surveillance and immuno-editing","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"R18-3-20210227","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"R19-3-20210227","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00001813-199504000-00013","article-title":"Bryostatin 1 enhances lymphokine activated killer (LAK) sensitivity and modulates the \u03b21 integrin profile of cultured human tumor cells","volume":"6","author":"Correale","year":"1995","journal-title":"Anticancer Drugs"},{"key":"R20-3-20210227","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/0277-5379(91)90018-9","article-title":"Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro","volume":"27","author":"Correale","year":"1991","journal-title":"Eur J Cancer"},{"key":"R21-3-20210227","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/cimm.1997.1169","article-title":"Immunosensitization of prostate carcinoma cell lines for lymphocyte(CTL, TIL, LAK)-mediated apoptosis via the fas-fas-ligand pathway of cytotoxicity","volume":"180","author":"Frost","year":"1997","journal-title":"Cell Immunol"},{"key":"R22-3-20210227","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002620100229","article-title":"Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes","volume":"50","author":"Bergmann-Leitner","year":"2001","journal-title":"Cancer Immunol Immunother"},{"key":"R23-3-20210227","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-05-2059","article-title":"A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer","volume":"12","author":"Arlen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R24-3-20210227","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-05-1761","article-title":"Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis","volume":"12","author":"Gelbard","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R25-3-20210227","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-05-0018","article-title":"Phase I\/II combined chemo-immunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer","volume":"11","author":"Weihrauch","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R26-3-20210227","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF01880660","article-title":"New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: thymidylate synthase","volume":"16","author":"Van der Wilt","year":"1994","journal-title":"Pharm World Sci"},{"key":"R27-3-20210227","first-page":"388","article-title":"Cancer: Principles and Practice of Oncology. 6th ed","author":"Chu","year":"2001"},{"key":"R28-3-20210227","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"2002","journal-title":"Semin Oncol"},{"key":"R29-3-20210227","first-page":"227","article-title":"Cellular and molecular pharmacology of oxaliplatin","volume":"1","author":"Raymond","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"R30-3-20210227","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1006242005837","article-title":"A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and\/or metastatic solid tumors","volume":"16","author":"Berlin","year":"1998","journal-title":"Invest N Drugs"},{"key":"R31-3-20210227","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2000.18.20.3553","article-title":"Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies","volume":"18","author":"Madajewicz","year":"2000","journal-title":"J Clin Oncol"},{"issue":"11","key":"R32-3-20210227","first-page":"52","article-title":"Novel combinations with oxaliplatin","volume":"14","author":"Mani","year":"2000","journal-title":"Oncology"},{"key":"R33-3-20210227","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050955","article-title":"Supra-additive effect of 2\u2032, 2\u2032-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines","volume":"44","author":"Faivre","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"R34-3-20210227","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000055290","article-title":"Gemcitabine: progress in the treatment of pancreatic cancer","volume":"60","author":"Heinemann","year":"2001","journal-title":"Oncology"},{"key":"R35-3-20210227","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bjc.6601045","article-title":"A novel bi-weekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid","volume":"89","author":"Correale","year":"2003","journal-title":"Br J Cancer"},{"key":"R36-3-20210227","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/sj.bjc.6601783","article-title":"A novel biweekly multi-drug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pre-treated patients with advanced colorectal carcinoma","volume":"90","author":"Correale","year":"2004","journal-title":"Br J Cancer"},{"key":"R37-3-20210227","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.4161\/cbt.4.10.2206","article-title":"Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation","volume":"4","author":"Caraglia","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"R38-3-20210227","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.4049\/jimmunol.138.6.1657","article-title":"NK susceptibility varies inversely with target cell class I HLA antigen expression","volume":"138","author":"Storkus","year":"1987","journal-title":"J Immunol"},{"key":"R39-3-20210227","first-page":"51","article-title":"A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field","volume":"97","author":"Boyum","year":"1968","journal-title":"Scand J Clin Lab Invest"},{"key":"R40-3-20210227","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.152.1.163","article-title":"Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains","volume":"152","author":"Parker","year":"1994","journal-title":"J Immunol"},{"key":"R41-3-20210227","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/JCM.37.3.649-652.1999","article-title":"Laboratory diagnosis of Toscana virus infection by enzyme immunoassay with recombinant viral nucleoprotein","volume":"37","author":"Soldateschi","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R42-3-20210227","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0065-2776(08)60023-1","article-title":"Dendritic cells","volume":"72","author":"Bell","year":"1999","journal-title":"Adv Immunol"},{"key":"R43-3-20210227","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI114525","article-title":"Granulocyte-macrophage colony stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro","volume":"85","author":"Markowicz","year":"1990","journal-title":"J Clin Invest"},{"key":"R44-3-20210227","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1189\/jlb.0603272","article-title":"The main function of IL-2 is to promote the development of T regulatory cells","volume":"74","author":"Malek","year":"2003","journal-title":"J Leuk Biol"},{"key":"R45-3-20210227","first-page":"17.2.1","article-title":"Current Protocols in Immunology Inc","author":"Schneck","year":"2000"},{"key":"R46-3-20210227","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1084\/jem.185.12.2043","article-title":"HLA-2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes form beta 2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta m double knockout mice","volume":"185","author":"Pascolo","year":"1997","journal-title":"J Exp Med"},{"key":"R47-3-20210227","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4049\/jimmunol.175.2.820","article-title":"Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro","volume":"175","author":"Correale","year":"2005","journal-title":"J Immunol"},{"key":"R48-3-20210227","doi-asserted-by":"crossref","first-page":"8950","DOI":"10.1200\/JCO.2005.12.147","article-title":"Strong immunological and anti-tumor activity of chemo-immunotherapy with Gemcitabine+FOLFOX 4 (GOLF) poly-chemotherapy followed by subcutaneous (sc) granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) in high risk metastatic colorectal carcinoma patients","volume":"23","author":"Correale","year":"2005","journal-title":"J Clin Oncol"},{"key":"R49-3-20210227","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Statist Assoc"},{"key":"R50-3-20210227","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/S0024-3205(96)00686-8","article-title":"Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens","volume":"60","author":"Melero","year":"1997","journal-title":"Life Sci"},{"key":"R51-3-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(05)25001-5","article-title":"The role of regulatory T cells in controlling immunologic self-tolerance","volume":"225","author":"Takahashi","year":"2003","journal-title":"Int Rev Cytol"},{"key":"R52-3-20210227","first-page":"111","article-title":"CD4+CD25+ T cells as key regulators of immune responses","volume":"13","author":"Dubois","year":"2003","journal-title":"Eur J Dermatol"},{"key":"R53-3-20210227","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(03)00359-5","article-title":"Tumor specific human CD4+ regulatory T cells and their ligands: implication for immunotherapy","volume":"20","author":"Wang","year":"2004","journal-title":"Immunity"},{"key":"R54-3-20210227","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4049\/jimmunol.172.2.923","article-title":"Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo form CD25\u2013CD4+ precursors in a thymus independent process","volume":"172","author":"Karim","year":"2004","journal-title":"J Immunol"},{"key":"R55-3-20210227","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/nm1312","article-title":"Lymphopenia and interleukin-2 therapy alter homeostasis of CD+CD25+ regulatory T cells","volume":"11","author":"Zhang","year":"2005","journal-title":"Nat Med"},{"key":"R56-3-20210227","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1179\/joc.2001.13.5.519","article-title":"In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase","volume":"13","author":"Correale","year":"2001","journal-title":"J Chemother"},{"key":"R57-3-20210227","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-tolerizing host tumor specific CD8T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J Immunol"},{"key":"R58-3-20210227","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res"},{"key":"R59-3-20210227","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res"},{"key":"R60-3-20210227","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/0008-5472.CAN-05-2967","article-title":"Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity","volume":"66","author":"van der Most","year":"2006","journal-title":"Cancer Res"},{"key":"R61-3-20210227","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1517\/14656566.6.16.2813","article-title":"Combining cancer vaccines with chemotherapy","volume":"6","author":"Chong","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"R62-3-20210227","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00262-004-0638-1","article-title":"Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas","volume":"54","author":"Plate","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"R63-3-20210227","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.mpa.0000191651.32420.41","article-title":"Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer","volume":"32","author":"Bang","year":"2005","journal-title":"Pancreas"},{"key":"R64-3-20210227","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0959-8049(01)00063-6","article-title":"Recruitment of dendritic cells and enhanced antigen specific immune-reactivity in cancer patients treated with hrGM-CSF (molgramostim) and hr IL-2: results from a phase Ib clinical trial","volume":"37","author":"Correale","year":"2001","journal-title":"Eur J Cancer"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e31815b69c8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T07:32:44Z","timestamp":1684222364000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200802000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31815b69c8","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}